CICigna
Is the price fair?
Neither cheap nor expensive: nothing decisive, though cheap vs its sector.
In its normal range: P/E 11.7 vs a 12.8 median over 30 quarters (−9% vs median).
Sector median 22.6× across 130 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What CI's price assumes
Cigna trades at 11.7× earnings against 25.0× for the median Healthcare Plans name, cheaper than its own group.
Trailing P/E · Healthcare Plans median 25.0 · cheaper than the typical name in its group
- Price / sales
- 0.26
Price / sales · today's price, trailing year to Jun 30, 2026
- Price / book
- 1.73
Price / book · today's price, trailing year to Jun 30, 2026
- EV / sales
- 0.35
EV / sales
Details›
- Price / booktoday's price, trailing year to Jun 30, 2026
- 1.73
- EV / EBITtoday's price, trailing year to Jun 30, 2026
- 9.99
- EV / salestoday's price, trailing year to Jun 30, 2026
- 0.35
- Healthcare median P/E509 names
- 26.2
- Healthcare Plans median P/E11 names
- 25.0
- Market capitalisation
- $73.9B
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $282.19 |
| Its own P/E history, median | $309.01 |
| Its own P/E history, upper quartile | $363.74 |
| 52-week range | $240.32 – $305.80 |
| Today | $282.35 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.